Low skeletal muscle mass is highly prevalent in older cancer patients and affects 5% to 89%
depending on the type and stage of cancer. Low skeletal muscle mass is associated with …

Developing successful antineoplastic therapies has been a primary focus of cancer
research, whereas less attention has been directed at body composition and metabolism in …

Reductions in skeletal muscle mass and function are often reported in patients with cancer-
associated weight loss and are associated with reduced quality of life, impaired treatment …

Background Muscle dysfunction is a prevalent phenomenon in the oncology setting where
patients across a wide range of diagnoses are subject to impaired muscle function …

Background Low muscle in cancer is associated with an increase in treatment‐related
toxicities and is a predictor of cancer‐related and all‐cause mortality. The mechanisms of …

Loss of lean body develops from an imbalance in protein synthesis and catabolism and is
associated with a variety of different disease and nondisease states, including severe …

Cancer cachexia—cancer-associated body weight and muscle loss—is a significant
predictor of mortality and morbidity in cancer patients across a variety of cancer types …

Patients with cancer are at an increased risk for muscle loss via 2 distinct mechanisms:
sarcopenia, defined as the age‐associated decrease in muscle mass related to changes in …

Background & aims Muscle wasting in cancer negatively affects physical function and quality
of life. This study investigates amino acid metabolism and the association with muscle mass …

Progressive skeletal muscle wasting in cancer cachexia involves a process of dysregulated
protein synthesis and breakdown. This catabolism may be the result of mal‐nutrition, and an …